8-19954279-C-T

Variant summary

Our verdict is Pathogenic. The variant received 15 ACMG points: 15P and 0B. PM1PP2PP3_StrongPP5_Very_Strong

The NM_000237.3(LPL):​c.701C>T​(p.Pro234Leu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000322 in 1,613,972 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. P234P) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.000013 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000034 ( 0 hom. )

Consequence

LPL
NM_000237.3 missense

Scores

17
1
1

Clinical Significance

Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:11

Conservation

PhyloP100: 7.52

Publications

18 publications found
Variant links:
Genes affected
LPL (HGNC:6677): (lipoprotein lipase) LPL encodes lipoprotein lipase, which is expressed in heart, muscle, and adipose tissue. LPL functions as a homodimer, and has the dual functions of triglyceride hydrolase and ligand/bridging factor for receptor-mediated lipoprotein uptake. Severe mutations that cause LPL deficiency result in type I hyperlipoproteinemia, while less extreme mutations in LPL are linked to many disorders of lipoprotein metabolism. [provided by RefSeq, Jul 2008]
LPL Gene-Disease associations (from GenCC):
  • familial lipoprotein lipase deficiency
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: G2P, Laboratory for Molecular Medicine, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • hyperlipidemia, familial combined, LPL related
    Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Pathogenic. The variant received 15 ACMG points.

PM1
In a hotspot region, there are 7 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 2 uncertain in NM_000237.3
PP2
Missense variant in the gene, where a lot of missense mutations are associated with disease in ClinVar. The gene has 52 curated pathogenic missense variants (we use a threshold of 10). The gene has 10 curated benign missense variants. Trascript score misZ: -0.36753 (below the threshold of 3.09). GenCC associations: The gene is linked to familial lipoprotein lipase deficiency, hyperlipidemia, familial combined, LPL related.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.992
PP5
Variant 8-19954279-C-T is Pathogenic according to our data. Variant chr8-19954279-C-T is described in ClinVar as Pathogenic/Likely_pathogenic. ClinVar VariationId is 1527.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
LPLNM_000237.3 linkc.701C>T p.Pro234Leu missense_variant Exon 5 of 10 ENST00000650287.1 NP_000228.1 P06858A0A1B1RVA9

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
LPLENST00000650287.1 linkc.701C>T p.Pro234Leu missense_variant Exon 5 of 10 NM_000237.3 ENSP00000497642.1 P06858
LPLENST00000520959.5 linkc.*128C>T downstream_gene_variant 4 ENSP00000428496.1 E7EW14

Frequencies

GnomAD3 genomes
AF:
0.0000132
AC:
2
AN:
152088
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000294
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.0000398
AC:
10
AN:
251454
AF XY:
0.0000368
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.0000462
Gnomad NFE exome
AF:
0.0000703
Gnomad OTH exome
AF:
0.000163
GnomAD4 exome
AF:
0.0000342
AC:
50
AN:
1461884
Hom.:
0
Cov.:
32
AF XY:
0.0000303
AC XY:
22
AN XY:
727244
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
33480
American (AMR)
AF:
0.0000224
AC:
1
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26134
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39700
South Asian (SAS)
AF:
0.00
AC:
0
AN:
86258
European-Finnish (FIN)
AF:
0.0000374
AC:
2
AN:
53420
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5768
European-Non Finnish (NFE)
AF:
0.0000405
AC:
45
AN:
1112004
Other (OTH)
AF:
0.0000331
AC:
2
AN:
60396
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.474
Heterozygous variant carriers
0
4
8
11
15
19
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000132
AC:
2
AN:
152088
Hom.:
0
Cov.:
33
AF XY:
0.0000135
AC XY:
1
AN XY:
74292
show subpopulations
⚠️ The allele balance in gnomAD version 4 Genomes is significantly skewed from the expected value of 0.5.
African (AFR)
AF:
0.00
AC:
0
AN:
41388
American (AMR)
AF:
0.00
AC:
0
AN:
15266
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5196
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4822
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10600
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
314
European-Non Finnish (NFE)
AF:
0.0000294
AC:
2
AN:
68030
Other (OTH)
AF:
0.00
AC:
0
AN:
2090
⚠️ The allele balance in gnomAD version 4 Genomes is significantly skewed from the expected value of 0.5. (p-value = 0.002339), which strongly suggests a high chance of mosaicism in these individuals.
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.350
Heterozygous variant carriers
0
0
1
1
2
2
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0000513
Hom.:
0
Bravo
AF:
0.0000113
ExAC
AF:
0.0000494
AC:
6
EpiCase
AF:
0.00
EpiControl
AF:
0.000119

ClinVar

Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:11
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Hyperlipoproteinemia, type I Pathogenic:3
Jan 05, 2022
DASA
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The c.701C>T;p.(Pro234Leu) missense variant has been observed in affected individual(s) and ClinVar contains an entry for this variant (ClinVar ID: 1527; OMIM: 609708.0009; PMID: 8099055; 1511985; 2038366) - PS4. Well-established in vitro or in vivo functional studies support a damaging effect on the gene or gene product (PMID: 8099055) - PS3_supporting. The variant is located in a mutational hot spot and/or critical and well-established functional domain (Lipase) - PM1. The variant is present at low allele frequencies population databases (rs118204060– gnomAD 0.0001315%; ABraOM no frequency - http://abraom.ib.usp.br/) - PM2_supporting. The p.(Pro234Leu) was detected in trans with a pathogenic variant (PMID: 8099055) - PM3. The variant co-segregated with disease in multiple affected family members (PMID: 8099055; 1511985) - PP1_strong. Multiple lines of computational evidence support a deleterious effect on the gene or gene product - PP3. In summary, the currently available evidence indicates that the variant is pathogenic. -

Jun 06, 2022
Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

ACMG classification criteria: PS4 strong, PM2 moderated, PM3 strong, PP3 supporting -

May 01, 1993
OMIM
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:literature only

- -

Hyperlipidemia, familial combined, LPL related Pathogenic:2
Dec 05, 2018
Institute of Human Genetics, University of Leipzig Medical Center
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

May 04, 2022
Mendelics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Pathogenic:2
Jun 02, 2022
GeneDx
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Reported as the most prevalent founder mutation in the French Canadaian population (Normand et al., 1992; Wood et al., 1993; Bijvoet et al., 1996); Published functional studies suggest impaired LPL activity in transfected cells (Ma et al., 1991).; In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 31589614, 30150141, 32041611, 2038366, 24366202, 29748148, 8099055, 8728325, 27055971, 17560523, 1511985) -

Dec 02, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 234 of the LPL protein (p.Pro234Leu). This variant is present in population databases (rs118204060, gnomAD 0.007%). This missense change has been observed in individual(s) with clinical features of chylomicronemia (PMID: 2038366, 24366202, 29748148, 30150141). ClinVar contains an entry for this variant (Variation ID: 1527). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt LPL protein function with a positive predictive value of 80%. For these reasons, this variant has been classified as Pathogenic. -

Cardiovascular phenotype Pathogenic:2
Oct 23, 2024
Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, Montreal Heart Institute
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

PS4, PP1_strong, PM1, PM2, PM3, PS3_supp, PP2, PP3, PP5 -

Nov 04, 2019
Ambry Genetics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The p.P234L pathogenic mutation (also known as c.701C>T), located in coding exon 5 of the LPL gene, results from a C to T substitution at nucleotide position 701. The proline at codon 234 is replaced by leucine, an amino acid with similar properties. This variant (also referred to as P207L) has been reported as a French Canadian founder mutation and has been detected in the homozygous and compound heterozygous state in numerous individuals with familial chylomicronemia syndrome with reduced lipoprotein lipase enzyme activity (Ma Y et al. N. Engl. J. Med., 1991 Jun;324:1761-6; Yang Y et al. J Genet Genomics, 2007 May;34:381-91; Sacks FM et al. JAMA Intern Med, 2014 Mar;174:443-7; Ariza MJ et al. J Clin Lipidol 2018 Aug;12:1482-1492.e3; Hegele RA et al. J Clin Lipidol 2018 Apr;12:920-927.e4; Normand T et al. Hum. Genet., 1992 Aug;89:671-5). This variant has also been detected in the heterozygous state in individuals with hypertriglyceridemia (Yang Y et al. J Genet Genomics, 2007 May;34:381-91). This mutation has been reported to result in a catalytically defective protein with abnormal conformation (Ma Y et al. N. Engl. J. Med., 1991 Jun;324:1761-6; Peterson J et al. J. Lipid Res., 2002 Mar;43:398-406). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -

Hyperlipidemia, familial combined, LPL related;C0023817:Hyperlipoproteinemia, type I Pathogenic:1
Jun 19, 2024
Fulgent Genetics, Fulgent Genetics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

LPL-related disorder Pathogenic:1
Feb 06, 2024
PreventionGenetics, part of Exact Sciences
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:clinical testing

The LPL c.701C>T variant is predicted to result in the amino acid substitution p.Pro234Leu. This variant has been reported in the homozygous or compound heterozygous state in multiple patients with lipoprotein lipase deficiency and familial chylomicronemia syndrome (FCS) (Hegele et al. 2018. PubMed ID: 29748148; Ariza et al. 2018. PubMed ID: 30150141; Rodrigues et al. 2016. PubMed ID: 27055971). This variant is also a common cause of lipoprotein lipase deficiency among French Canadians, and functional data indicate the p.Pro234Leu substitution reduces LPL protein activity significantly (Ma et al. 1991. PubMed ID: 2038366). In summary, we interpret this variant as pathogenic. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.92
BayesDel_addAF
Pathogenic
0.37
D
BayesDel_noAF
Pathogenic
0.49
CADD
Pathogenic
29
DANN
Uncertain
1.0
DEOGEN2
Pathogenic
0.91
D;D
Eigen
Pathogenic
0.96
Eigen_PC
Pathogenic
0.93
FATHMM_MKL
Pathogenic
0.98
D
LIST_S2
Pathogenic
0.98
.;D
M_CAP
Pathogenic
0.43
D
MetaRNN
Pathogenic
0.99
D;D
MetaSVM
Pathogenic
0.99
D
MutationAssessor
Pathogenic
3.2
M;M
PhyloP100
7.5
PrimateAI
Pathogenic
0.83
D
PROVEAN
Pathogenic
-9.8
D;.
REVEL
Pathogenic
0.82
Sift
Pathogenic
0.0
D;.
Sift4G
Pathogenic
0.0
D;.
Polyphen
1.0
D;D
Vest4
0.99
MutPred
0.96
Gain of sheet (P = 0.0827);Gain of sheet (P = 0.0827);
MVP
0.97
MPC
0.45
ClinPred
0.99
D
GERP RS
6.2
Varity_R
0.97
gMVP
0.97

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs118204060; hg19: chr8-19811790; API